Compare CINT & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CINT | PROK |
|---|---|---|
| Founded | 1995 | 2015 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 391.6M | 359.4M |
| IPO Year | 2021 | 2021 |
| Metric | CINT | PROK |
|---|---|---|
| Price | $3.11 | $1.67 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 7 |
| Target Price | $5.62 | ★ $6.25 |
| AVG Volume (30 Days) | 55.4K | ★ 1.4M |
| Earning Date | 11-11-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $893,000.00 |
| Revenue This Year | $16.56 | N/A |
| Revenue Next Year | $9.87 | $7.83 |
| P/E Ratio | $17.94 | ★ N/A |
| Revenue Growth | N/A | ★ 1075.00 |
| 52 Week Low | $2.80 | $1.30 |
| 52 Week High | $6.06 | $3.48 |
| Indicator | CINT | PROK |
|---|---|---|
| Relative Strength Index (RSI) | 46.66 | 49.14 |
| Support Level | $2.81 | $1.55 |
| Resistance Level | $3.62 | $1.76 |
| Average True Range (ATR) | 0.16 | 0.10 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 46.03 | 48.39 |
CI&T Inc operates as a partner in tech-integrated business solutions, helping organizations address complex challenges by integrating business approach, technology, and artificial intelligence into a single, coherent operating model. It is mainly engaged in the development of customizable software through the implementation of software solutions, including machine learning, artificial intelligence, data analytics, cloud migration and mobility technologies. The company provides technology services to various industry verticals, including Financial Services, Consumer Goods, Technology and Communications, Retail and Industrial Goods, Life Sciences, among others. The majority of the revenue is derived from providing technology services. Geographically, maximum revenue is derived from Brazil.
ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.